DEPO-PROVERA LAWSUIT
DEPO-PROVERA LAWSUIT

DEPO-PROVERA
Brain Tumor Lawsuit
What Is Depo-Provera?
Depo-Provera is a widely used contraceptive marketed under the brand names Depo-Provera and the lower-dose Depo-SubQ Provera 104. Depo-Provera is a hormonal birth control injection approved by the U.S. Food and Drug Administration (FDA) in 1992 and inhibits ovulation by thickening cervical mucus and thinning the uterine lining. It is typically into the arm or the buttocks every 12 weeks. Depo-Provera is highly effective and may also be prescribed for managing other conditions, such as:
-
Hormonal imbalances
-
Menstrual disorders
-
Postpartum bleeding
-
Reduce cancer risk
-
Reduce ovarian cysts
-
Uterine fibroids
-
Cancer treatment
-
Chronic pelvic pain
-
Contraception
-
Endometriosis
-
Hirsutism

In recent years, Depo-Provera has come under scrutiny after research linked the drug’s ingredients to an increased risk of meningioma brain tumors.
How Does Depo-Provera Cause Brain Tumors?
Medical research suggests that prolonged use of medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, is associated with a more than fivefold increase in the risk of brain tumors. MPA binds to progesterone receptors in the protective tissues surrounding the brain and spinal cord, leading to abnormal cell growth that can contribute to the formation of meningiomas.
Given this elevated risk and the estimated 74 million users worldwide, Depo-Provera represents a potentially significant public health concern.

What Are the Symptoms of Meningioma Brain Tumors?
Symptoms of meningioma vary depending on the size and location of the tumor and include:
-
Blurred or double vision
-
Confusion or disorientation
-
Difficult speaking
-
Headaches, particularly in the morning
-
Hearing loss
-
Loss of balance or vertigo
-
Loss of smell
-
Memory loss
-
Seizures
-
Tinnitus (ringing in the ears)
-
Weakness or numbness in limbs

What Is a Depo-Provera Lawsuit?
Depo-Provera has been linked to an increased risk of meningioma and other brain tumors. Early findings suggest that Pfizer knew, or should have known, about these risks but failed to adequately warn healthcare professionals and consumers.
Women who have received at least two Depo-Provera injections may be eligible for compensation if they have been diagnosed with any of the following conditions:
-
Benign or malignant brain tumors
-
Meningioma
-
Pseudotumor cerebri
We are currently investigating claims on behalf of women who were administered Depo-Provera and later diagnosed with brain tumors that might have been prevented with proper warnings.
As awareness of the risks associated with Depo-Provera grows, we anticipate a significant increase in lawsuits against Pfizer in the coming years.